MDLN 10-Q Quarterly Reports

Medline Inc. reported solid revenue growth of 10.7% for the quarter ended March 28, 2026, reaching $7.35 billion, driven primarily by increased volumes across its U.S. operations, particularly within the acute care segment. Despite this top-line expansion, net income saw a decline of 25.8% to $239 million, largely due to a significant increase in Cost of Goods Sold (up 14.3%) and Selling, General, and Administrative (SG&A) expenses (up 14.8%). Higher import costs related to tariffs and increased compensation and distribution expenses were key drivers for the rise in operating costs. The company also experienced a substantial decrease in interest expense, down 35.2% to $136 million, following the repayment of significant debt portions using IPO proceeds in the prior year, which positively impacted profitability. The balance sheet remains strong with $2.24 billion in cash and cash equivalents and $946 million in available liquidity under its revolving credit facility. The company continues to manage its financial obligations, with a total indebtedness of $12.76 billion as of the quarter's end.